--- title: "Allworth Financial LP Purchases New Position in Illumina, Inc. $ILMN" type: "News" locale: "en" url: "https://longbridge.com/en/news/296694311.md" description: "Allworth Financial LP initiated a new position in Illumina (ILMN) during Q2, acquiring 5,976 shares valued at approximately $1.05 million, per SEC filings. Other institutions like BlackRock and Mitsubishi UFJ also increased stakes. Meanwhile, insiders SVPs Patricia Leckman and Christensen Jakob Wedel sold shares under Rule 10b5-1 plans. Illumina recently reported strong quarterly earnings of $1.31 EPS, beating estimates, with revenue up 9.4% year-over-year." datetime: "2026-08-23T07:20:44.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296694311.md) - [en](https://longbridge.com/en/news/296694311.md) - [zh-HK](https://longbridge.com/zh-HK/news/296694311.md) generator: "portal-rs" --- # Allworth Financial LP Purchases New Position in Illumina, Inc. $ILMN Allworth Financial LP acquired a new position in Illumina, Inc. (NASDAQ:ILMN - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 5,976 shares of the life sciences company's stock, valued at approximately $1,051,000. - GRAIL: Biotech Stock Targeting $100B Cancer Market Several other hedge funds and other institutional investors have also added to or reduced their stakes in ILMN. BlackRock Inc. bought a new stake in Illumina in the 2nd quarter worth about $3,374,423,000. Plato Investment Management Ltd bought a new position in Illumina during the 2nd quarter valued at about $948,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Illumina during the 2nd quarter valued at about $30,501,000. Edmond DE Rothschild Holding S.A. purchased a new stake in shares of Illumina during the 2nd quarter valued at about $129,792,000. Finally, Impact Partnership Wealth LLC boosted its holdings in shares of Illumina by 235.8% during the 1st quarter. Impact Partnership Wealth LLC now owns 11,080 shares of the life sciences company's stock valued at $1,366,000 after acquiring an additional 7,780 shares during the last quarter. 89.42% of the stock is owned by institutional investors. ## Insider Activity at Illumina In other Illumina news, SVP Patricia Leckman sold 783 shares of Illumina stock in a transaction on Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the sale, the senior vice president directly owned 21,259 shares in the company, valued at approximately $3,456,500.81. The trade was a 3.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 1,033 shares of Illumina stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the sale, the senior vice president directly owned 14,023 shares in the company, valued at $2,685,684.96. This trade represents a 6.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 2,095,958 shares of company stock worth $401,720,974. 2.90% of the stock is currently owned by corporate insiders. ## Illumina Stock Performance - Strategic Buy Lights Up This Biotech Stock: Time to Invest? Shares of ILMN opened at $219.40 on Friday. The business has a 50-day simple moving average of $188.01 and a two-hundred day simple moving average of $152.44. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $220.43. The stock has a market cap of $33.13 billion, a price-to-earnings ratio of 40.93, a PEG ratio of 3.09 and a beta of 1.45. Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating analysts' consensus estimates of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to analysts' expectations of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business's quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the firm earned $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, analysts expect that Illumina, Inc. will post 5.36 EPS for the current year. ## Key Stories Impacting Illumina - Palantir Was Left Out of the S&P 500; It Still Looks Like a Buy Here are the key news stories impacting Illumina this week: - Positive Sentiment: Illumina’s latest quarterly results exceeded expectations, with earnings of $1.31 per share versus the $1.23 consensus estimate and revenue of $1.16 billion versus expectations of $1.13 billion. Revenue increased 9.4% year over year, while fiscal 2026 EPS guidance remains $5.30-$5.40. Illumina stock information - Positive Sentiment: Several institutional investors increased their positions, including Marshall Wace, Cresset Asset Management and Empowered Funds. Hedge funds and other institutions collectively own approximately 89.4% of ILMN shares, indicating strong professional-investor participation. - Neutral Sentiment: Analyst opinions remain mixed. Zacks Research upgraded the stock to “strong buy,” and Leerink Partners raised its target to $210, while Deutsche Bank downgraded the shares to “hold.” The overall consensus rating is “hold,” with an average target of $188.40—below recent trading levels. Analyst coverage of Illumina - Negative Sentiment: Director Keith A. Meister sold 679,574 Illumina shares from August 19 through August 21 for approximately $145.6 million. The transactions reduced his ownership by roughly one-third, although he still holds about 1.41 million shares. The size and timing of the sales may raise concerns about insider conviction, even though the filings do not establish the reason for the transactions. SEC insider ownership filing - Negative Sentiment: SVP Christensen Jakob Wedel also sold 1,033 shares under a pre-arranged Rule 10b5-1 trading plan. The smaller, planned transaction is less concerning than Meister’s sales but adds to the recent pattern of insider selling. Illumina insider trading alert ## Analyst Ratings Changes A number of brokerages have recently commented on ILMN. Guggenheim lifted their price target on shares of Illumina from $200.00 to $226.00 and gave the stock a "buy" rating in a research note on Friday, July 31st. Sanford C. Bernstein restated a "market perform" rating and set a $215.00 price objective on shares of Illumina in a research report on Friday, July 31st. Leerink Partners increased their price target on Illumina from $175.00 to $210.00 and gave the company an "outperform" rating in a report on Friday, July 17th. Deutsche Bank Aktiengesellschaft downgraded Illumina to a "hold" rating in a research note on Wednesday, August 5th. Finally, Barclays lifted their price objective on Illumina from $145.00 to $160.00 and gave the stock an "underweight" rating in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Illumina has an average rating of "Hold" and a consensus target price of $188.40. **Read Our Latest Research Report on Illumina** ## Illumina Profile (Free Report) Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications. The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays. ## See Also - Five stocks we like better than Illumina - 2 Biotech Stocks Shaping Up for Major Breakouts - 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs - 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run - Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit? **Want to see what other hedge funds are holding ILMN?** Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report). *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Illumina Right Now? Before you consider Illumina, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list. While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [ILMN.US](https://longbridge.com/en/quote/ILMN.US.md) - [BLK.US](https://longbridge.com/en/quote/BLK.US.md) - [GRAL.US](https://longbridge.com/en/quote/GRAL.US.md) - [MUFG.US](https://longbridge.com/en/quote/MUFG.US.md) - [8306.JP](https://longbridge.com/en/quote/8306.JP.md) - [PLTR.US](https://longbridge.com/en/quote/PLTR.US.md) - [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md) - [BTX.US](https://longbridge.com/en/quote/BTX.US.md) - [BIT.RT*.US](https://longbridge.com/en/quote/BIT.RT*.US.md) - [BDJ.US](https://longbridge.com/en/quote/BDJ.US.md) - [BSTZ.US](https://longbridge.com/en/quote/BSTZ.US.md) - [BIT.RT.US](https://longbridge.com/en/quote/BIT.RT.US.md) ## Related News & Research - [Why Illumina (ILMN) Stock Climbed And What Investors Are Watching Now](https://longbridge.com/en/news/296706451.md) - [OVERSEA CHINESE BANKING Corp Ltd Takes $6.71 Million Position in Illumina, Inc. $ILMN](https://longbridge.com/en/news/296598679.md) - [Top Illumina Executive Unloads Shares in Notable Insider Move](https://longbridge.com/en/news/296572634.md) - [Illumina SVP Jakob Wedel Christensen sells 1,033 shares worth $197,040.16](https://longbridge.com/en/news/296531379.md) - [Illumina completes $300 million notes offering due 2029](https://longbridge.com/en/news/296140807.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**